We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
P-407-induced Mouse Model of Dose-controlled Hyperlipidemia and Atherosclerosis: 25 Years Later.
Journal of Cardiovascular Pharmacology 2017 November
The poloxamer 407 (P-407) nongenetic, nondiet-induced mouse model of dose-controlled hyperlipidemia and atherosclerosis was first introduced in 1992. Dyslipidemia is produced in C57BL/6 mice of either sex after intraperitoneal administration of P-407 that is a polyether-based nonionic surface active agent. Aortic atherosclerotic lesions begin to form after 1 month of repeated P-407 administration and obtain maximum size, numerical density, and human-like pathological features by 4 months. Our laboratory published a review of this model in 2004, although an update would seem both appropriate and timely based on new findings since 2004. Using P-407-treated mice, we have investigated the effect that hyperlipidemia has on the activity of several classes of proteases in the heart, liver, and serum; extensively characterized lipoprotein fractions and subfractions associated with atherogenic plasma lipids; investigated whether several key vascular cell adhesion molecules were perturbed; and determined whether the biological activity of 2 peroxisome proliferator-activated receptors was modulated both in vitro and in vivo. Based on our findings since 2004, as well as those before 2004 (1992-2004), we would strongly suggest that the P-407-induced hyperlipidemic mouse model represents a convenient, inexpensive, and well-documented alternative mouse model with which to study cardiovascular heart disease arising from dyslipidemia and atherosclerosis.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app